arrow_back Back to App

Accelerating Drug Approval: Integrating FDA Processes with Operation Warp Speed

This resolution aims to speed up access to new drugs and biological products, such as vaccines. Citizens can expect faster market availability of innovative therapies, potentially improving treatment access and public health protection. These changes are intended to streamline approval processes, reducing the waiting time for new medical solutions.
Key points
Integrating Operation Warp Speed processes into Food and Drug Administration (FDA) operations to accelerate drug approval.
Issuing guidance to help speed up the development and approval of new drugs and biological products.
Utilizing existing safety and scientific data from already approved products for faster evaluation of new ones.
Collecting interim data during trials to allow for parallel assessment and simultaneous approval of multiple drugs.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HRES_876
Sponsor: Rep. Burgess, Michael C. [R-TX-26]
Process start date: 2022-01-19
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Expressing the sense that the process behind Operation Warp Speed should be integrated within operations at the Food and Drug Administration.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HRES_876.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-01-19.

What are the main provisions?

Key points include:

  • Integrating Operation Warp Speed processes into Food and Drug Administration (FDA) operations to accelerate drug approval.
  • Issuing guidance to help speed up the development and approval of new drugs and biological products.
  • Utilizing existing safety and scientific data from already approved products for faster evaluation of new ones.
  • Collecting interim data during trials to allow for parallel assessment and simultaneous approval of multiple drugs.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Burgess, Michael C. [R-TX-26].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

CATEGORIES

Health